TCGA-D8-A13Y-01A-11R-A115-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 58
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.600
- G2M_CHECKPOINT+0.510
- PANCREAS_BETA_CELLS+0.480
- SPERMATOGENESIS+0.410
- HEDGEHOG_SIGNALING+0.290
- MITOTIC_SPINDLE+0.290
- MYC_TARGETS_V1+0.240
- DNA_REPAIR+0.180
- MTORC1_SIGNALING+0.110
- WNT_BETA_CATENIN_SIGNALING+0.080
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.620
- INTERFERON_GAMMA_RESPONSE-0.590
- ALLOGRAFT_REJECTION-0.580
- IL6_JAK_STAT3_SIGNALING-0.510
- INFLAMMATORY_RESPONSE-0.500
- TNFA_SIGNALING_VIA_NFKB-0.470
- APICAL_SURFACE-0.430
- COMPLEMENT-0.400
- COAGULATION-0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-C4-A0EZ-01A-21R-A24X-07 | — | — | 0.934 |
| 2 | SRR13780269 | — | cohortSC | 0.926 |
| 3 | TCGA-86-8358-01A-11R-2326-07 | — | cohortA3 | 0.922 |
| 4 | SRR13780268 | — | cohortSC | 0.922 |
| 5 | BS_WH5HDE0A | medulloblastoma | — | 0.921 |
| 6 | TCGA-A1-A0SK-01A-12R-A084-07 | — | E | 0.918 |
| 7 | TCGA-56-7223-01A-11R-2045-07 | — | cohortMD1 | 0.915 |
| 8 | TCGA-G2-A2EL-01A-12R-A18C-07 | — | — | 0.908 |
| 9 | 91648 | EPN | Supratentorial EPN | 0.905 |
| 10 | BS_NKRYMHEP | medulloblastoma | — | 0.905 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.600 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.510 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.480 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.410 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.290 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.290 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.240 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.180 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.110 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.080 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.070 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.040 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.030 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |